# US 2023/0414773 A1 · Elp fusion proteins for controlled and sustained release

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0414773 A1
- Document ID: US20230414773A1
- Status: Published application
- Kind: A1
- Application number: 18/323,208
- Filed: 2023-05-24
- Published: 2023-12-28
- Earliest claimed: 2014-11-21
- Applicants: ImmunoForge Co., LTD
- Inventors: Jamie JOWETT; David James BALLANCE
- Web page: https://patentgrep.com/patent/US20230414773A1

## CPC

- A61K 47/6435: {the peptide or protein in the drug conjugate being a connective tissue peptide, e.g. collagen, fibronectin or gelatin}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 38/14: Peptides containing saccharide radicals; Derivatives thereof {, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin}
- A61K 38/26: Glucagons
- A61K 38/27: Growth hormone [GH], i.e. somatotropin
- A61K 38/28: Insulins
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/02: Inorganic compounds
- A61K 47/64: Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent (peptidic linkers A61K47/65)
- A61P 35/00: Antineoplastic agents
- A61K 31/196: the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
- A61K 31/277: having a ring, e.g. verapamil
- A61K 31/337: having four-membered rings, e.g. taxol
- A61K 31/475: having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine (vincamine A61K31/4375)
- A61K 31/704: attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)}
- A61K 2300/00: Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- C07K 16/26: against hormones {; against hormone releasing or inhibiting factors}
- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present disclosure provides pharmaceutical formulations for sustained release, and methods for delivering a treatment regimen with a combination of sustained release and long half-life formulations. The disclosure provides improved pharma-cokinetics for peptide and small molecule drugs.

## Claims

### Claim at position 1

1-28. (canceled)

### Claim 29

A sustained release pharmaceutical formulation comprising:
a therapeutic agent, the therapeutic agent comprising an active agent and an ELP amino acid sequence comprising [VPGXG]144 or [XPGVG]144, where each X is selected from V, G, and A, and wherein the ELP exhibits a transition temperature between 26° C. and 37° C., and one or more pharmaceutically acceptable excipients.

### Claim 30 (depends on 29)

The pharmaceutical formulation of claim 29, wherein the formulation provides slow absorption from an injection site upon administration, wherein the absorption is characterized by a Tmax of greater than 5 hours.

### Claim 31 (depends on 30)

The pharmaceutical formulation of claim 30, wherein the formulation provides a flat PK profile upon administration, as compared to the PK profile for the active agent in the absence of said amino acid sequence.

### Claim 32

(canceled)

### Claim 33 (depends on 29)

The pharmaceutical formulation of claim 29, wherein formation of a reversible matrix at body temperature reverses as protein concentration decreases.

### Claim 34 (depends on 29)

The pharmaceutical formulation of claim 29, wherein V, G, and A are at a ratio selected from the group consisting of
a) 5:3:2;
b) 7:2:0;
c) 7:0:2;
d) 6:0:3;
e) 5:2:2; and
f) 5:0:4.

### Claim 35 (depends on 29)

The pharmaceutical formulation of claim 29, wherein the ELP comprises an ELP unit selected from [VPGXG]144, where each X is V.

### Claim 36 (depends on 29)

The pharmaceutical formulation of claim 29, wherein the active agent is a protein.

### Claim 37 (depends on 36)

The pharmaceutical formulation of claim 36, wherein the therapeutic agent is a recombinant fusion protein between the protein active agent and said amino acid sequence.

### Claim 38 (depends on 36)

The pharmaceutical formulation of claim 36, wherein the protein active agent has a circulatory half-life in the range of from about 30 seconds to about 10 hours, or about 30 second to about 1 hour.

### Claim 39 (depends on 36)

The pharmaceutical formulation of claim 36, wherein the active agent is a GLP-1 receptor agonist or derivative thereof, a VPAC2 selective agonist or a derivative thereof, a GIP receptor agonist or a derivative thereof, a glucagon receptor agonist or a derivative thereof, exendin-4 or a derivative thereof, or insulin or a derivative thereof.

### Claim 40 (depends on 39)

The pharmaceutical formulation of claim 39, wherein the formulation is a co-formulation comprising at least two of a GLP1 receptor agonist, a glucagon receptor agonist, a GIP receptor agonist, exendin-4, and insulin.

### Claim 41 (depends on 29)

The pharmaceutical formulation of claim 29, wherein the therapeutic agent is a chemical conjugate between the active agent and said amino acid sequence.

### Claim 42 (depends on 41)

The pharmaceutical formulation of claim 41, wherein the active agent is a chemotherapeutic agent, such as a chemotherapeutic agent selected from methotrexate, daunomycin, mitomycin, cisplatin, vincristine, epirubicin, fluorouracil, verapamil, cyclophosphamide, cytosine arabinoside, aminopterin, bleomycin, mitomycin C, democolcine, etoposide, mithramycin, chlorambucil, melphalan, daunorubicin, doxorubicin, tamoxifen, paclitaxel, vinblastine, camptothecin, actinomycin D, cytarabine, and combrestatin.

### Claim 43 (depends on 42)

The pharmaceutical formulation of claim 42, wherein the therapeutic agent is present in the range of about 0.5 mg/mL to about 200 mg/mL.

### Claim 44

(canceled)

### Claim 45 (depends on 34)

The pharmaceutical formulation of claim 34, wherein the therapeutic agent is present in the range of about 50 mg/mL to about 125 mg/mL, or the range of about 75 mg/mL to about 110 mg/mL.

### Claim at position 19

46-47. (canceled)

### Claim 48 (depends on 34)

The pharmaceutical composition of claim 34, wherein a storage temperature is less than about 40° C., or less than about 37° C., or less than about 30° C., or less than about 27° C., or less than about 25° C.

### Claim 49 (depends on 29)

The pharmaceutical formulation of claim 29, wherein the formulation comprises two or more of calcium chloride, magnesium chloride, potassium chloride, potassium phosphate monobasic, sodium chloride, sodium chloride, polysorbate 20, sodium phosphate, sodium phosphate monobasic, and sodium phosphate dibasic.

### Claim 50 (depends on 49)

The pharmaceutical formulation of claim 49, wherein the formulation comprises sodium phosphate, sodium chloride and polysorbate 20.

### Claim 51

(canceled)

### Claim 52 (depends on 29)

The pharmaceutical formulation of claim 29, wherein the formulation is packaged in the form of pre-dosed pens or syringes for administration once per week, twice per week, or from one to eight times per month.

### Claim 53 (depends on 29)

A method for delivering a sustained release regimen of a therapeutic agent, comprising, administering the formulation of claim 29 to a subject in need, wherein the formulation is administered from about 1 to about 8 times per month.

### Claim at position 26

54-57. (canceled)
